Translating cancer epigenomics into the clinic: focus on lung cancer

Bird, 2007, Perceptions of epigenetics, Nature, 447, 396, 10.1038/nature05913 Rodriguez-Paredes, 2011, Cancer epigenetics reaches mainstream oncology, Nat Med, 17, 330, 10.1038/nm.2305 Siegel, 2017, Cancer Statistics, 2017, CA Cancer J Clin, 67, 7, 10.3322/caac.21387 Aberle, 2011, Reduced lung-cancer mortality with low-dose computed tomographic screening, N Engl J Med, 365, 395, 10.1056/NEJMoa1102873 Walter, 2016, Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the randomised, controlled NELSON trial, Lancet Oncol, 17, 907, 10.1016/S1470-2045(16)30069-9 Marshall, 2013, Screening for lung cancer with low-dose computed tomography: a review of current status, J Thorac Dis, 5, S524 Portela, 2010, Epigenetic modifications and human disease, Nat Biotechnol, 28, 1057, 10.1038/nbt.1685 Greger, 1989, Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma, Hum Genet, 83, 155, 10.1007/BF00286709 Sandoval, 2012, Cancer epigenomics: beyond genomics, Curr Opin Genet Dev, 22, 50, 10.1016/j.gde.2012.02.008 Sheaffer, 2016, DNA hypomethylation Contributes to genomic instability and Intestinal cancer Initiation, Cancer Prev Res (phila), 9, 534, 10.1158/1940-6207.CAPR-15-0349 Esteller, 2008, Epigenetics in cancer, N Engl J Med, 358, 1148, 10.1056/NEJMra072067 Damiani, 2008, Carcinogen-induced gene promoter hypermethylation is mediated by DNMT1 and causal for transformation of immortalized bronchial epithelial cells, Cancer Res, 68, 9005, 10.1158/0008-5472.CAN-08-1276 Kim, 2006, Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer, Cancer, 107, 1042, 10.1002/cncr.22087 Husni, 2016, DNMT3a expression pattern and its prognostic value in lung adenocarcinoma, Lung Cancer, 97, 59, 10.1016/j.lungcan.2016.04.018 Daskalos, 2011, Global DNA hypomethylation-induced DeltaNp73 transcriptional activation in non-small cell lung cancer, Cancer Lett, 300, 79, 10.1016/j.canlet.2010.09.009 Brzezianska, 2013, The significance of epigenetic alterations in lung carcinogenesis, Mol Biol Rep, 40, 309, 10.1007/s11033-012-2063-4 Zhao, 2015, Diagnostic value of SHOX2 DNA methylation in lung cancer: a meta-analysis, Onco Targets Ther, 8, 3433 Villalba, 2016, Epigenetic alterations leading to TMPRSS4 promoter hypomethylation and protein overexpression predict poor prognosis in squamous lung cancer patients, Oncotarget, 7, 22752, 10.18632/oncotarget.8045 Xie, 2015, Detection of MGMT promoter methylation in glioblastoma using pyrosequencing, Int J Clin Exp Pathol, 8, 1790 Alelu-Paz, 2012, DNA methylation, histone modifications, and signal transduction pathways: a close relationship in malignant gliomas pathophysiology, J Signal Transduct, 2012, 956958, 10.1155/2012/956958 Esteller, 2000, Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents, N Engl J Med, 343, 1350, 10.1056/NEJM200011093431901 Bannister, 2011, Regulation of chromatin by histone modifications, Cell Res, 21, 381, 10.1038/cr.2011.22 Parbin, 2014, Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer, J Histochem Cytochem, 62, 11, 10.1369/0022155413506582 Strahl, 2000, The language of covalent histone modifications, Nature, 403, 41, 10.1038/47412 Lee, 2010, The language of histone crosstalk, Cell, 142, 682, 10.1016/j.cell.2010.08.011 Tan, 2011, Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification, Cell, 146, 1016, 10.1016/j.cell.2011.08.008 Ren, 2014, HDAC as a therapeutic target for treatment of endometrial cancers, Curr Pharm Des, 20, 1847, 10.2174/13816128113199990528 Jiao, 2014, Histone deacetylase 3 promotes pancreatic cancer cell proliferation, invasion and increases drug-resistance through histone modification of P27, P53 and Bax, Int J Oncol, 45, 1523, 10.3892/ijo.2014.2568 Song, 2005, Increased expression of histone deacetylase 2 is found in human gastric cancer, APMIS, 113, 264, 10.1111/j.1600-0463.2005.apm_04.x Fraga, 2005, Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer, Nat Genet, 37, 391, 10.1038/ng1531 Barlesi, 2007, Global histone modifications predict prognosis of resected non small-cell lung cancer, J Clin Oncol, 25, 4358, 10.1200/JCO.2007.11.2599 Van Den Broeck, 2008, Loss of histone H4K20 trimethylation occurs in preneoplasia and influences prognosis of non-small cell lung cancer, Clin Cancer Res, 14, 7237, 10.1158/1078-0432.CCR-08-0869 Huang, 2015, Non-coding RNA: a new tool for the diagnosis, prognosis, and therapy of small cell lung cancer, J Thorac Oncol, 10, 28, 10.1097/JTO.0000000000000394 Martens-Uzunova, 2013, Beyond microRNA–novel RNAs derived from small non-coding RNA and their implication in cancer, Cancer Lett, 340, 201, 10.1016/j.canlet.2012.11.058 Lee, 1993, The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14, Cell, 75, 843, 10.1016/0092-8674(93)90529-Y Mari-Alexandre, 2016, miRNAs regulation and its role as biomarkers in endometriosis, Int J Mol Sci, 17 Ramon, 2012, microRNAs related to angiogenesis are dysregulated in endometrioid endometrial cancer, Hum Reprod, 27, 3036, 10.1093/humrep/des292 Lan, 2015, MicroRNAs as potential biomarkers in cancer: opportunities and challenges, Biomed Res Int, 2015, 125094, 10.1155/2015/125094 Olive, 2010, mir-17-92, a cluster of miRNAs in the midst of the cancer network, Int J Biochem Cell Biol, 42, 1348, 10.1016/j.biocel.2010.03.004 Hayashita, 2005, A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation, Cancer Res, 65, 9628, 10.1158/0008-5472.CAN-05-2352 Braza-Boils, 2014, MicroRNA expression profile in endometriosis: its relation to angiogenesis and fibrinolytic factors, Hum Reprod, 29, 978, 10.1093/humrep/deu019 Crea, 2014, The non-coding transcriptome as a dynamic regulator of cancer metastasis, Cancer Metastasis Rev, 33, 1, 10.1007/s10555-013-9455-3 Mitchell, 2008, Circulating microRNAs as stable blood-based markers for cancer detection, Proc Natl Acad Sci U S A, 105, 10513, 10.1073/pnas.0804549105 Weber, 2010, The microRNA spectrum in 12 body fluids, Clin Chem, 56, 1733, 10.1373/clinchem.2010.147405 Rapisuwon, 2016, Circulating biomarkers to monitor cancer progression and treatment, Comput Struct Biotechnol J, 14, 211, 10.1016/j.csbj.2016.05.004 Jarry, 2014, The validity of circulating microRNAs in oncology: five years of challenges and contradictions, Mol Oncol, 8, 819, 10.1016/j.molonc.2014.02.009 Diaz-Lagares, 2016, Epigenetic inactivation of the p53-induced long noncoding RNA TP53 target 1 in human cancer, Proc Natl Acad Sci U S A, 113, E7535, 10.1073/pnas.1608585113 Diaz-Lagares, 2016, A novel epigenetic signature for early diagnosis in lung cancer, Clin Cancer Res, 22, 3361, 10.1158/1078-0432.CCR-15-2346 Sandoval, 2011, Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome, Epigenetics, 6, 692, 10.4161/epi.6.6.16196 Moran, 2016, Validation of a DNA methylation microarray for 850,000 CpG sites of the human genome enriched in enhancer sequences, Epigenomics, 8, 389, 10.2217/epi.15.114 Booth, 2014, Quantitative sequencing of 5-formylcytosine in DNA at single-base resolution, Nat Chem, 6, 435, 10.1038/nchem.1893 Ziller, 2015, Coverage recommendations for methylation analysis by whole-genome bisulfite sequencing, Nat Methods, 12, 230, 10.1038/nmeth.3152 Farlik, 2015, Single-cell DNA methylome sequencing and bioinformatic inference of epigenomic cell-state dynamics, Cell Rep, 10, 1386, 10.1016/j.celrep.2015.02.001 Johann, 2016, Atypical teratoid/rhabdoid tumors are comprised of three epigenetic subgroups with distinct enhancer landscapes, Cancer Cell, 29, 379, 10.1016/j.ccell.2016.02.001 Warton, 2014, Methylation-capture and Next-Generation Sequencing of free circulating DNA from human plasma, BMC Genomics, 15, 476, 10.1186/1471-2164-15-476 Soto, 2016, The impact of next-generation sequencing on the DNA methylation-based translational cancer research, Transl Res, 169, 1, 10.1016/j.trsl.2015.11.003 Furey, 2012, ChIP-seq and beyond: new and improved methodologies to detect and characterize protein-DNA interactions, Nat Rev Genet, 13, 840, 10.1038/nrg3306 Shankaranarayanan, 2011, Single-tube linear DNA amplification (LinDA) for robust ChIP-seq, Nat Methods, 8, 565, 10.1038/nmeth.1626 Li, 2014, Chromatin interaction analysis with paired-end Tag (ChIA-PET) sequencing technology and application, BMC Genomics, 15, S11, 10.1186/1471-2164-15-S12-S11 Ferracin, 2011, MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin, J Pathol, 225, 43, 10.1002/path.2915 Huang, 2013, Characterization of human plasma-derived exosomal RNAs by deep sequencing, BMC Genomics, 14, 319, 10.1186/1471-2164-14-319 Sundar, 2017, DNA methylation profiling in peripheral lung tissues of smokers and patients with COPD, Clin Epigenetics, 9, 38, 10.1186/s13148-017-0335-5 Gao, 2015, DNA methylation changes of whole blood cells in response to active smoking exposure in adults: a systematic review of DNA methylation studies, Clin Epigenetics, 7, 113, 10.1186/s13148-015-0148-3 Zochbauer-Muller, 2002, Aberrant DNA methylation in lung cancer: biological and clinical implications, Oncologist, 7, 451, 10.1634/theoncologist.7-5-451 Sundar, 2011, Lung cancer and its association with chronic obstructive pulmonary disease: update on nexus of epigenetics, Curr Opin Pulm Med, 17, 279, 10.1097/MCP.0b013e3283477533 Sundar, 2014, Cigarette smoke induces distinct histone modifications in lung cells: implications for the pathogenesis of COPD and lung cancer, J Proteome Res, 13, 982, 10.1021/pr400998n Sundar, 2013, Oxidative stress and chromatin remodeling in chronic obstructive pulmonary disease and smoking-related diseases, Antioxid Redox Signal, 18, 1956, 10.1089/ars.2012.4863 Soares do Amaral, 2017, Noncoding RNA profiles in tobacco- and Alcohol-associated diseases, Genes, 8, 6, 10.3390/genes8010006 Xi, 2010, Cigarette smoke induces C/EBP-beta-mediated activation of miR-31 in normal human respiratory epithelia and lung cancer cells, PLoS One, 5, e13764, 10.1371/journal.pone.0013764 Xi, 2013, Cigarette smoke mediates epigenetic repression of miR-487b during pulmonary carcinogenesis, The J Clin Invest, 123, 1241, 10.1172/JCI61271 Nagathihalli, 2012, Smoking induces epithelial-to-mesenchymal transition in non-small cell lung cancer through HDAC-mediated downregulation of E-cadherin, Mol Cancer Ther, 11, 2362, 10.1158/1535-7163.MCT-12-0107 Tellez, 2011, EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells, Cancer Res, 71, 3087, 10.1158/0008-5472.CAN-10-3035 Shi, 2016, Analysis of plasma microRNA expression profiles revealed different cancer susceptibility in healthy young adult smokers and middle-aged smokers, Oncotarget, 7, 21676, 10.18632/oncotarget.7866 Banerjee, 2015, Quantification of plasma microRNAs in a group of healthy smokers, ex-smokers and non-smokers and correlation to biomarkers of tobacco exposure, Biomarkers, 20, 123, 10.3109/1354750X.2014.1000970 Badrnya, 2014, Smoking alters circulating plasma microvesicle pattern and microRNA signatures, Thromb Haemost, 112, 128, 10.1160/TH13-11-0977 Takahashi, 2013, Cigarette smoking substantially alters plasma microRNA profiles in healthy subjects, Toxicol Appl Pharmacol, 272, 154, 10.1016/j.taap.2013.05.018 Lu, 2017, Feedback circuitry via let-7c between lncRNA CCAT1 and c-Myc is involved in cigarette smoke extract-induced malignant transformation of HBE cells, Oncotarget, 8, 19285, 10.18632/oncotarget.15195 Lu, 2016, Epigenetic silencing of miR-218 by the lncRNA CCAT1, acting via BMI1, promotes an altered cell cycle transition in the malignant transformation of HBE cells induced by cigarette smoke extract, Toxicol Appl Pharmacol, 304, 30, 10.1016/j.taap.2016.05.012 Liu, 2015, Epithelial-mesenchymal transition and cancer stem cells, mediated by a long non-coding RNA, HOTAIR, are involved in cell malignant transformation induced by cigarette smoke extract, Toxicol Appl Pharmacol, 282, 9, 10.1016/j.taap.2014.10.022 Roychowdhury, 2016, Translating cancer genomes and transcriptomes for precision oncology, CA Cancer J Clin, 66, 75, 10.3322/caac.21329 Shrager, 2014, Rapid learning for precision oncology, Nat Rev Clin Oncol, 11, 109, 10.1038/nrclinonc.2013.244 Sandoval, 2013, A prognostic DNA methylation signature for stage I non-small-cell lung cancer, J Clin Oncol, 31, 4140, 10.1200/JCO.2012.48.5516 Wrangle, 2014, Functional identification of cancer-specific methylation of CDO1, HOXA9, and TAC1 for the diagnosis of lung cancer, Clin Cancer Res, 20, 1856, 10.1158/1078-0432.CCR-13-2109 Samuel, 2016, Genome-wide DNA methylation analysis reveals epigenetic Dysregulation of MicroRNA-34A in TP53-associated cancer susceptibility, J Clin Oncol, 10.1200/JCO.2016.67.6940 Ilse, 2014, Analysis of SHOX2 methylation as an aid to cytology in lung cancer diagnosis, Cancer Genomics Proteomics, 11, 251 Schmidt, 2010, SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates, BMC Cancer, 10, 600, 10.1186/1471-2407-10-600 Kneip, 2011, SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma, J Thorac Oncol, 6, 1632, 10.1097/JTO.0b013e318220ef9a Weiss, 2017, Validation of the SHOX2/PTGER4 DNA methylation marker panel for plasma-based discrimination between patients with malignant and nonmalignant lung disease, J Thorac Oncol, 12, 77, 10.1016/j.jtho.2016.08.123 Ponomaryova, 2013, Potentialities of aberrantly methylated circulating DNA for diagnostics and post-treatment follow-up of lung cancer patients, Lung Cancer, 81, 397, 10.1016/j.lungcan.2013.05.016 Ostrow, 2010, Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCR, Clin Cancer Res, 16, 3463, 10.1158/1078-0432.CCR-09-3304 Begum, 2011, An epigenetic marker panel for detection of lung cancer using cell-free serum DNA, Clin Cancer Res, 17, 4494, 10.1158/1078-0432.CCR-10-3436 Hoque, 2005, Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects, J Clin Oncol, 23, 6569, 10.1200/JCO.2005.07.009 Richiardi, 2009, Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients, J Clin Oncol, 27, 3161, 10.1200/JCO.2008.18.2485 Sunami, 2009, Multimarker circulating DNA assay for assessing blood of prostate cancer patients, Clin Chem, 55, 559, 10.1373/clinchem.2008.108498 Lee, 2009, Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer, Clin Cancer Res, 15, 6185, 10.1158/1078-0432.CCR-09-0111 Lofton-Day, 2008, DNA methylation biomarkers for blood-based colorectal cancer screening, Clin Chem, 54, 414, 10.1373/clinchem.2007.095992 Semaan, 2016, SEPT9 and SHOX2 DNA methylation status and its utility in the diagnosis of colonic adenomas and colorectal adenocarcinomas, Clin Epigenetics, 8, 100, 10.1186/s13148-016-0267-5 Dietrich, 2013, Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant and malignant pleural effusions, PLoS One, 8, e84225, 10.1371/journal.pone.0084225 Perkins, 2017, Droplet-based digital PCR: application in cancer research, Adv Clin Chem, 79, 43, 10.1016/bs.acc.2016.10.001 Singh, 2016, Circulating microRNAs in cancer: Hope or hype?, Cancer Lett, 381, 113, 10.1016/j.canlet.2016.07.002 Gyoba, 2016, Diagnosing lung cancers through Examination of Micro-RNA biomarkers in blood, plasma, serum and sputum: a review and summary of current Literature, Int J Mol Sci, 17, 494, 10.3390/ijms17040494 Hennessey, 2012, Serum microRNA biomarkers for detection of non-small cell lung cancer, PLoS One, 7, e32307, 10.1371/journal.pone.0032307 Chen, 2012, Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis, Int J Cancer, 130, 1620, 10.1002/ijc.26177 Jiang, 2013, Relative expressions of miR-205-5p, miR-205-3p, and miR-21 in tissues and serum of non-small cell lung cancer patients, Mol Cell Biochem, 383, 67, 10.1007/s11010-013-1755-y Wang, 2015, Early detection of lung cancer in serum by a panel of MicroRNA biomarkers, Clin Lung Cancer, 16, 313, 10.1016/j.cllc.2014.12.006 Sozzi, 2014, Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study, J Clin Oncol, 32, 768, 10.1200/JCO.2013.50.4357 Boeri, 2012, Role of microRNAs in lung cancer: microRNA signatures in cancer prognosis, Cancer J, 18, 268, 10.1097/PPO.0b013e318258b743 Hessels, 2003, DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer, Eur Urol, 44, 8, 10.1016/S0302-2838(03)00201-X Lee, 2011, Prostate cancer: diagnostic performance of the PCA3 urine test, Nat Rev Urol, 8, 123, 10.1038/nrurol.2011.10 Qi, 2016, Circulating long non-coding RNAs in cancer: current status and future perspectives, Mol Cancer, 15, 39, 10.1186/s12943-016-0524-4 Mottamal, 2015, Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents, Molecules, 20, 3898, 10.3390/molecules20033898 Vendetti, 2013, Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases, Expert Opin Biol Ther, 13, 1273, 10.1517/14712598.2013.819337 Jurkowski, 2015, Synthetic epigenetics-towards intelligent control of epigenetic states and cell identity, Clin Epigenetics, 7, 18, 10.1186/s13148-015-0044-x Falahi, 2013, Towards sustained silencing of HER2/neu in cancer by epigenetic editing, Mol Cancer Res, 11, 1029, 10.1158/1541-7786.MCR-12-0567 Garcia-Bloj, 2016, Waking up dormant tumor suppressor genes with zinc fingers, TALEs and the CRISPR/dCas9 system, Oncotarget, 7, 60535, 10.18632/oncotarget.11142 Huisman, 2015, Prolonged re-expression of the hypermethylated gene EPB41L3 using artificial transcription factors and epigenetic drugs, Epigenetics, 10, 384, 10.1080/15592294.2015.1034415 Oronsky, 2014, Episensitization: therapeutic tumor resensitization by epigenetic agents: a review and reassessment, Anticancer Agents Med Chem, 14, 1121, 10.2174/1871520614666140418144610 Christman, 2002, 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy, Oncogene, 21, 5483, 10.1038/sj.onc.1205699 Hollenbach, 2010, A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines, PLoS One, 5, e9001, 10.1371/journal.pone.0009001 Gallipoli, 2015, Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia, Ther Adv Hematol, 6, 103, 10.1177/2040620715577614 Finelli, 2016, Clinical impact of hypomethylating agents in the treatment of Myelodysplastic syndromes, Curr Pharm Des, 22, 2349, 10.2174/1381612822666160310145040 Lavelle, 2012, Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine, Blood, 119, 1240, 10.1182/blood-2011-08-371690 Gnyszka, 2013, DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer, Anticancer Res, 33, 2989 You, 2014, Zebularine inhibits the growth of A549 lung cancer cells via cell cycle arrest and apoptosis, Mol Carcinog, 53, 847, 10.1002/mc.22042 Nakamura, 2013, DNA methyltransferase inhibitor zebularine inhibits human hepatic carcinoma cells proliferation and induces apoptosis, PLoS One, 8, e54036, 10.1371/journal.pone.0054036 Graca, 2014, Anti-tumoral effect of the non-nucleoside DNMT inhibitor RG108 in human prostate cancer cells, Curr Pharm Des, 20, 1803, 10.2174/13816128113199990516 Mann, 2007, FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma, Oncologist, 12, 1247, 10.1634/theoncologist.12-10-1247 Piekarz, 2009, Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma, J Clin Oncol, 27, 5410, 10.1200/JCO.2008.21.6150 Whittaker, 2010, Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma, J Clin Oncol, 28, 4485, 10.1200/JCO.2010.28.9066 Juergens, 2011, Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer, Cancer Discov, 1, 598, 10.1158/2159-8290.CD-11-0214 Alzoubi, 2016, Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer, Oncotarget, 7, 44505, 10.18632/oncotarget.9887 Del Bufalo, 2014, Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer, Mol Cancer, 13, 230, 10.1186/1476-4598-13-230 Zuco, 2015, Targeting the invasive phenotype of cisplatin-resistant non-small cell lung cancer cells by a novel histone deacetylase inhibitor, Biochem Pharmacol, 94, 79, 10.1016/j.bcp.2015.01.002 Ruiz, 2015, Entinostat (SNDX-275) for the treatment of non-small cell lung cancer, Expert Opin Investig Drugs, 24, 1101, 10.1517/13543784.2015.1056779 Hideshima, 2011, Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma, Mol Cancer Ther, 10, 2034, 10.1158/1535-7163.MCT-11-0433 Wolfe, 2000, DNA recognition by Cys2His2 zinc finger proteins, Annu Rev Biophys Biomol Struct, 29, 183, 10.1146/annurev.biophys.29.1.183 Rivenbark, 2012, Epigenetic reprogramming of cancer cells via targeted DNA methylation, Epigenetics, 7, 350, 10.4161/epi.19507 Nunna, 2014, Targeted methylation of the epithelial cell adhesion molecule (EpCAM) promoter to silence its expression in ovarian cancer cells, PLoS One, 9, e87703, 10.1371/journal.pone.0087703 Schnell, 2013, EpCAM: structure and function in health and disease, Biochim Biophys Acta, 1828, 1989, 10.1016/j.bbamem.2013.04.018 Guo, 2015, Endometriosis and ovarian cancer: potential benefits and harms of screening and risk-reducing surgery, Fertil Steril, 104, 813, 10.1016/j.fertnstert.2015.08.006 Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 Siddique, 2013, Targeted methylation and gene silencing of VEGF-A in human cells by using a designed Dnmt3a-Dnmt3L single-chain fusion protein with increased DNA methylation activity, J Mol Biol, 425, 479, 10.1016/j.jmb.2012.11.038 Snowden, 2002, Gene-specific targeting of H3K9 methylation is sufficient for initiating repression in vivo, Curr Biol, 12, 2159, 10.1016/S0960-9822(02)01391-X Mojica, 2005, Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements, J Mol Evol, 60, 174, 10.1007/s00239-004-0046-3 Brouns, 2008, Small CRISPR RNAs guide antiviral defense in prokaryotes, Science, 321, 960, 10.1126/science.1159689 Hilton, 2015, Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers, Nat Biotechnol, 33, 510, 10.1038/nbt.3199 Thakore, 2015, Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements, Nat Methods, 12, 1143, 10.1038/nmeth.3630 Vojta, 2016, Repurposing the CRISPR-Cas9 system for targeted DNA methylation, Nucleic Acids Res, 44, 5615, 10.1093/nar/gkw159 Stepper, 2017, Efficient targeted DNA methylation with chimeric dCas9-Dnmt3a-Dnmt3L methyltransferase, Nucleic Acids Res, 45, 1703, 10.1093/nar/gkw1112 Choudhury, 2016, CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter, Oncotarget, 7, 46545, 10.18632/oncotarget.10234 Xu, 2016, A CRISPR-based approach for targeted DNA demethylation, Cell Discov, 2, 16009, 10.1038/celldisc.2016.9 Du, 2016, An introduction to CRISPR technology for genome activation and repression in Mammalian cells, Cold Spring Harb Protoc, 2016